Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Current Assets (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Current Assets for 12 consecutive years, with $195.6 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets rose 3163.64% year-over-year to $195.6 million; the TTM value through Mar 2026 reached $195.6 million, up 3163.64%, while the annual FY2025 figure was $236.7 million, N/A changed from the prior year.
  • Current Assets hit $195.6 million in Q1 2026 for Crescent Biopharma, down from $236.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $236.7 million in Q4 2025 and bottomed at $6.0 million in Q1 2025.
  • Average Current Assets over 5 years is $79.2 million, with a median of $57.1 million recorded in 2022.
  • Year-over-year, Current Assets plummeted 81.99% in 2025 and then skyrocketed 3163.64% in 2026.
  • Crescent Biopharma's Current Assets stood at $50.7 million in 2022, then decreased by 13.65% to $43.8 million in 2023, then crashed by 64.27% to $15.6 million in 2024, then soared by 1412.58% to $236.7 million in 2025, then fell by 17.36% to $195.6 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $195.6 million, $236.7 million, and $134.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.